Speakers

Expand/Collapse

Charles Cheung
Senior Scientist
Abbvie

Day Two

Thursday 24 September, 2020

9:25 am | RSL-DVDs: An Improved Disulfide-Reinforced Single Linker DVD-Ig Bispecific Format

Paul Widboom
Associate Director
Adimab LLC

Day One

Wednesday 23 September, 2020

2:05 pm | Panel Discussion: Exploring Strategies to Overcome On-Target Off-Tumour Toxicities

Pre-Conference Focus Day

11:25 am | Discovering the Balance Between Safety & Efficacy

Jonathan Lai
Associate Professor - Biochemistry
Albert Einstein College of Medicine

Peter Ellmark
VP Discovery
Alligator Bioscience AB

Matthew Chun
Scientist
Amgen

Day Two

Thursday 24 September, 2020

4:00 pm | Strategies for Targeting Solid & Hematologic Cancers using Bispecific T-Cell Engager (BiTE®) Molecules

John Delaney
Executive Director - Research
Amgen Inc.

Ryan Potts
Cell & Molecular Biology, Associate Member, St. Jude Faculty
Amgen/St Jude Children’s Research Center

Day Two

Thursday 24 September, 2020

3:10 pm | Small Molecule Bispecifics for Targeted Protein Degradation

Jane Gross
Chief Scientific Officer
Aptevo Therapeutics Inc.

Day One

Wednesday 23 September, 2020

2:05 pm | Panel Discussion: Exploring Strategies to Overcome On-Target Off-Tumour Toxicities

Pre-Conference Focus Day

10:35 am | Fireside Chat: Evaluating the Criteria Essential to Success in the Increasingly Competitive CD3 Bispecific Field

Alison Betts
Senior Director of Scientific Collaborations, Fellow of Modeling & Simulation Applied
Applied Biomath

Day One

Wednesday 23 September, 2020

3:35 pm |

Amrik Basran
Chief Scientific Officer
Avacta Group Plc

Day Two

Thursday 24 September, 2020

9:00 am | Affimer Therapeutics: A Versatile Antibody Mimetic Platform for the Generation of Bispecific Immunotherapies

Marta Germani
Research Analyst
Beacon

Day One

Wednesday 23 September, 2020

9:00 am | Review of the Bispecific Landscape

Eugene Zhukovsky
Chief Scientific Officer - Research
Biomunex Pharmaceuticals

Day Two

Thursday 24 September, 2020

3:35 pm | Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space - What Does the Future of the BioSpecific Look Like?

9:50 am | Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations

Rakesh Dixit
President & Chief Executive Officer
Bionavigen

Pre-Conference Focus Day

9:00 am | Learning from Successful & Failed Bispecific Biologics

Steven Chamow
President
Chamow & Associates Inc.

Pre-Conference Focus Day

2:45 pm | Workshop - The Process of CMO Selection for Bispecific Antibody Development: Matching Capabilities to Need

Ambrose Williams
Scientist, Tech Dev
Genentech

Stephanie Truhlar
Senior Research Advisor, AME/Biotechnology Discovery Research
Eli Lilly and Company

Vittal Shivva
Scientist
Genentech

Jonah Rainey
Vice President - Cell Biology & Immunology
Gritstone Oncology

Day One

Wednesday 23 September, 2020

3:35 pm |

Rick Austin
Senior Director
Harpoon Therapeutics Inc.

Pre-Conference Focus Day

12:50 pm | TriTACs Are T-cell Engaging Drugs for Treatment of Solid Tumors

Horacio Nastri
Executive Director
Incyte Corporation

Day One

Wednesday 23 September, 2020

2:05 pm | Panel Discussion: Exploring Strategies to Overcome On-Target Off-Tumour Toxicities

Day Two

Thursday 24 September, 2020

9:50 am | Panel Discussion: Demonstrating the Superiority of Bispecifics in Immuno-Oncology Indications in Comparison with Antibody Combinations

Indrajeet Singh
Principal Scientist
Johnson & Johnson

Pre-Conference Focus Day

1:35 pm | CD3 bi-specifics to CAR-T: Clinical Pharmacology Consideration from Preclinical to Clinical Development of T Cell Redirects

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Danielle Dettling
Senior Director, Research & Development
Maverick Therapeutics

Kalyan Pande
Associate Principal Scientist, Biologics Discovery
Merck & Co

Pieter Fokko van Loo
Director Oncology ‑ Immunology
Merus NV

Day Two

Thursday 24 September, 2020

1:35 pm | Triclonics™ ENGAGE: Trispecific Antibody Platform for the Discovery of Next Generation T-cell Engagers

Clara Domke
Senior Scientist Oncology Research
Molecular Partners AG

Day Two

Thursday 24 September, 2020

2:00 pm | Novel Therapeutic Design of Tumor-targeted CD40 Agonistic DARPin® Molecule Leads to Antitumor Activity with Limited Systemic Toxicity

Nimish Gera
Head of Biologics
Mythic Therapeutics

John Blankenship
Senior Investigator & Group Leader - Antibody Discovery
Novartis

Day Two

Thursday 24 September, 2020

3:35 pm | Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space - What Does the Future of the BioSpecific Look Like?

Gosia Nocula-Lugowska
Senior Principal Scientist - Antibody Discovery and Engineering
Pfizer

Pre-Conference Focus Day

1:15 pm | Discovery & Optimization of T-cell Bispecifics for the Treatment of Solid Tumors

Mohamed Elmeliegy
Associate Director - Clinical Pharmacology
Pfizer

Pre-Conference Focus Day

10:35 am | Fireside Chat: Evaluating the Criteria Essential to Success in the Increasingly Competitive CD3 Bispecific Field

11:00 am | An Industry Perspective on CD3 Bispecifics Starting Doses & Efficacious Dose Projections

Kara Olson
Senior Staff Scientist
Regeneron Pharmaceuticals

Pre-Conference Focus Day

9:25 am | Development of Novel Fully Human Bispecific Antibodies for Oncology

Aynur Hermann
Director, Therapeutic Proteins
Regeneron Pharmaceuticals

Jasmin Sydow-Andersen
Senior Scientist / Lab Head Mass Spectrometry
Roche

Fateme Tousi
Scientist
Sanofi

Wei Yan
Yan President & CEO
Sound Biologics

Nathan Trinklein
Chief Technology Officer
TeneoBio

Rastislav Tamaskovic
Researcher
University Medical Center Groningen

Day One

Wednesday 23 September, 2020

9:50 am | Revision of RTK Tumor Targeting: How to Design Truly Potent Bispecific & Biparatopic Agents

Andrew Tsourkas
Professor of Bioengineering
University of Pennsylvania

Day One

Wednesday 23 September, 2020

9:25 am | Engineering Proteins, Therapeutics & Antibodies to Enable their Efficient Cytosolic Delivery

Jeffrey Way
Senior Staff Scientist
Wyss Institute at Harvard University

John Burke
Co-Founder, President and CEO
Applied Biomath

John Desjarlais
Chief Scientific Officer
Xencor

Day One

Wednesday 23 September, 2020

3:35 pm |

Jonathan Davis
Head, Innovation
Invenra Inc.

Rupert Davies
Director, Pharmacokinetics
Zymeworks

Darshana Jani
Director, Global Bioanalysis
Agenus inc

Day One

Wednesday 23 September, 2020

2:05 pm | Panel Discussion: Exploring Strategies to Overcome On-Target Off-Tumour Toxicities